Q3 EPS Forecast for IDEAYA Biosciences Increased by Analyst

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) – Research analysts at Wedbush lifted their Q3 2025 earnings estimates for shares of IDEAYA Biosciences in a note issued to investors on Tuesday, September 2nd. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of $1.37 per share for the quarter, up from their prior estimate of ($0.94). The consensus estimate for IDEAYA Biosciences’ current full-year earnings is ($3.07) per share. Wedbush also issued estimates for IDEAYA Biosciences’ FY2025 earnings at ($1.29) EPS, Q1 2026 earnings at ($1.03) EPS, Q2 2026 earnings at ($1.07) EPS, Q3 2026 earnings at ($1.10) EPS, Q4 2026 earnings at ($0.56) EPS, FY2026 earnings at ($3.77) EPS, FY2027 earnings at ($3.48) EPS, FY2028 earnings at ($3.13) EPS and FY2029 earnings at ($0.77) EPS.

Several other equities analysts have also issued reports on IDYA. Royal Bank Of Canada raised shares of IDEAYA Biosciences from an “outperform” rating to a “moderate buy” rating and decreased their price target for the company from $57.00 to $30.00 in a report on Wednesday, July 9th. Wells Fargo & Company initiated coverage on shares of IDEAYA Biosciences in a report on Thursday, June 26th. They issued an “overweight” rating and a $44.00 price target for the company. Citigroup initiated coverage on shares of IDEAYA Biosciences in a report on Thursday. They issued an “outperform” rating for the company. JPMorgan Chase & Co. boosted their price target on shares of IDEAYA Biosciences from $72.00 to $74.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, Citizens Jmp started coverage on shares of IDEAYA Biosciences in a report on Thursday. They issued a “mkt outperform” rating and a $41.00 price target for the company. Twelve analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $45.77.

IDEAYA Biosciences Stock Up 5.1%

Shares of IDYA stock opened at $27.16 on Thursday. IDEAYA Biosciences has a 12-month low of $13.45 and a 12-month high of $37.99. The firm has a market capitalization of $2.38 billion, a price-to-earnings ratio of -7.17 and a beta of 0.12. The firm has a fifty day moving average of $23.66 and a 200-day moving average of $20.64.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.03). The firm had revenue of $6.00 million for the quarter, compared to the consensus estimate of $3.48 million. During the same period last year, the business earned ($0.68) earnings per share. The firm’s revenue for the quarter was up NaN% compared to the same quarter last year.

Institutional Investors Weigh In On IDEAYA Biosciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. bought a new stake in IDEAYA Biosciences during the 4th quarter worth about $47,000. CWM LLC lifted its position in IDEAYA Biosciences by 325.7% during the 1st quarter. CWM LLC now owns 2,371 shares of the company’s stock worth $39,000 after buying an additional 1,814 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in IDEAYA Biosciences by 180.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company’s stock worth $39,000 after buying an additional 1,546 shares in the last quarter. Signaturefd LLC lifted its position in IDEAYA Biosciences by 374.8% during the 1st quarter. Signaturefd LLC now owns 2,877 shares of the company’s stock worth $47,000 after buying an additional 2,271 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC bought a new stake in IDEAYA Biosciences during the 2nd quarter worth about $61,000. 98.29% of the stock is owned by institutional investors.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.